Selectivity and therapeutic inhibition of kinases: To be or not to be?

Nature Immunology

Volumn 10, Issue 4, 2009, Pages 356-360

  Ghoreschi, Kamran ^a   Laurence, Arian ^a   O'Shea, John J ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYCLOSPORIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GLUCOCORTICOID; IMATINIB; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE 3 INHIBITOR; JANUS KINASE INHIBITOR; LAPATINIB; LESTAURTINIB; LIPID; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHOTRANSFERASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; USTEKINUMAB;

ADVANCED CANCER; ANEMIA; ANKYLOSING SPONDYLITIS; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTERITIS; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STABILITY; ENZYME STRUCTURE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GRAFT REJECTION; HEAD AND NECK CARCINOMA; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; INFECTION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CANCER; KIDNEY GRAFT REJECTION; LIPID BLOOD LEVEL; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT MESOTHELIOMA; MELANOMA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; PANCREAS CANCER; PANCREAS TUMOR; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MODIFICATION; PSORIASIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHOSPHORYLATION; POLYCYTHEMIA VERA; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 62849094732     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.1701     Document Type: Article

References (44)

1. Fischer, E.H. & Krebs, E.G. Relationship of structure to function of muscle phosphorylase. Fed. Proc. 25, 1511-1520 (1966).
2. Venter, J.C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
3. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
4. Hunter, T. A thousand and one protein kinases. Cell 50, 823-829 (1987).
5. Pawson, T. Protein-tyrosine kinases. Getting down to specifics. Nature 373, 477-478 (1995).
6. Pawson, T. Protein modules and signalling networks. Nature 373 573-580 (1995).
7. Schindler, T. et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289, 1938-1942 (2000).
8. Daley, G.Q., Van Etten, R.A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990).
9. Druker, B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
10. O'Brien, S.G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
11. Druker, B.J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
12. Geyer, C.E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006).
13. Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
14. Cools, J. et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214 (2003).
15. S imon, M.P. et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 15, 95-98 (1997).
16. Baroni, S.S. et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. 354, 2667-2676 (2006).
17. Louvet, C. et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 105, 18895-18900 (2008).
18. Gorre, M.E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 876-880 (2001).
19. Azam, M., Seeliger, M.A., Gray, N.S., Kuriyan, J. & Daley, G.Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 15, 1109-1118 (2008).
20. Lee, J.C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746 (1994).
21. Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377 65-68 (1995).
22. Russell, S.M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797-800 (1995).
23. Karaghiosoff, M. et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13, 549-560 (2000).
24. Minegishi, Y. et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745-755 (2006).
25. Duerr, R.H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006).
26. Burton, P.R. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39, 1329-1337 (2007).
27. Leonardi, C.L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665-1674 (2008).
28. Changelian, P.S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878 (2003).
29. Kremer, J.M. et al. A randomized, double-blind placebo-controlled trial of 3 dose levels of CP-690,550 versus placebo in the treatment of active rheumatoid arthritis. Arthritis Rheum. 54, 4116 (2006).
30. Wilkinson, B., Chow, V., LaBadie, R., Zwillich, S.,H. & Cohen, S. Co-administration of an oral JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis. Arthritis Rheum. 58, S297 (2008).
31. Chan, G., Cunshan, W., Boy, M., Chow, V. & Herron, J. Dose-dependent reduction in psoriasis severity as evidence of immunosuppressive activityof an oral Jak3 inhibitor in humans. Am. J. Transplant. 6, S87 (2006).
32. van Gurp, E. et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: Preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am. J. Transplant. 8, 1711-1718 (2008).
33. Parganas, E. et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385-395 (1998).
34. Baxter, E.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (2005).
35. James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling-causes polycythaemia vera. Nature 434 1144-1148 (2005).
36. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferafive disorders. N. Engl. J. Med. 352, 1779-1790 (2005).
37. Levine, R.L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397 (2005).
38. Geron, I. et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 13, 321-330 (2008).
39. Wernig, G. et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13, 311-320 (2008).
40. Manshouri, T. et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 99, 1265-1273 (2008).
41. Williams, W. et al. A randomized placebo-controlled study of INCB018424, a selective Janus kinase 1&2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). Arthritis Rheum. 58, S431 (2008).
42. Weinblatt, M.E. et al. Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309-3318 (2008).
43. Engelman, J.A. et al. Effective use of P13K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008).
44. Apsel, B. et al. Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. chem. Biol. 4, 691-699 (2008).